<DOC>
	<DOCNO>NCT02983006</DOCNO>
	<brief_summary>The purpose study evaluate safety profile , tolerability , immunoregulatory ( pharmacodynamic ; PD ) activity DS-8273a administer combination nivolumab ( anti-PD-1 antibody ) subject unresectable Stage III Stage IV melanoma .</brief_summary>
	<brief_title>Study DS-8273a With Nivolumab Unresectable Stage III Stage IV Melanoma</brief_title>
	<detailed_description>Principal investigator hypothesize TRAIL D5 antibody DS-8273a administer combination nivolumab well tolerated addition DS-8273a augment clinical efficacy nivolumab .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<criteria>1 ) Signed Written Informed Consent The sign informed consent form prior performance study relate procedure consider part standard care . 2 ) Target Population 1 . Subjects ipilimumab naïve progressive unresectable Stage III Stage IV melanoma ; eligible patient may prior adjuvant therapy , include ipilimumab , treat 3 prior treatment metastatic melanoma [ eg , chemotherapy , biologic target therapy Interleukin2 ( IL2 ) ] . 2 . Histologic cytologic confirmation stage III stage IV melanoma 3 . Measurable disease baseline assess CT and/or MRI 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 5 . Screening laboratory value must meet follow criterion obtain within 7 day prior registration • White blood cell ( WBC ) ≥ 2000/μL • Neutrophils ≥ 1500/μL Platelets ≥ 100 x103/μL Hemoglobin &gt; 9.0 g/dL Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) creatinine clearance ( CrCl ) ≥ 40 mL/min ( use CockcroftGault formula ) : Female CrCl = ( 140 age year ) x weight kg x 0.85 72 x serum creatinine mg/dL Male CrCl = ( 140 age year ) x weight kg x 1.00 72 x serum creatinine mg/dL Aspartate aminotransferase ( AST ) /Alanine aminotransferase ( ALT ) ≤ 3 x ULN Total Bilirubin ≤ 1.5 x ULN ( except subject Gilbert Syndrome , total bilirubin &lt; 3.0 mg/dL ) 3 ) Age Reproductive Status Men woman ≥ 18 year old 1 . Men woman childbearing potential ( WOCBP ) must use acceptable method contraception avoid pregnancy throughout study , woman least 23 week last dose investigational product men least 31 week last dose investigational product manner risk pregnancy minimize . See Section 3.3.3 definition WOCBP . 2 . Women must negative serum pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 24 hour prior start investigational product . 1 ) Target Disease Exceptions ) Subjects know suspected brain metastasis , brain site disease exclude following exception . ) Subjects control brain metastasis ( radiographic progression least 4 week follow radiation and/or surgical treatment , steroid least 4 week , new progress neurological sign symptom ) allow . b ) Subjects history prior malignancy exception carcinoma situ cervix malignancy diagnose &gt; 2 year ago undergone potentially curative therapy evidence disease last ≥ 2 year deem investigator low risk recurrence . 2 ) Medical History Concurrent Diseases ) Active autoimmune disease history know suspect autoimmune disease exception subject isolate vitiligo , treat thyroiditis resolve childhood asthma/atopy . b ) Known human immunodeficiency virus ( HIV ) , active hepatitis A , hepatitis B C infection . c ) Evidence active infection require antibacterial , antiviral , antifungal therapy ≤ 7 day prior initiation study drug therapy ) History acute diverticulitis within last 6 month , current chronic diarrhea e ) Active peptic ulcer disease even asymptomatic f ) Prior organ allograft allogenic bone marrow transplantation g ) Uncontrolled significant cardiovascular disease include , limited , follow : ) Myocardial infarction within past 6 month ii ) Uncontrolled angina within past 6 month iii ) Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation Torsades de pointes ) . Controlled atrial fibrillation exclusion criterion . h ) Baseline toxicities prior anticancer treatment &gt; Grade 1. ) Inability venipunctured and/or tolerate venous access . j ) Any major surgery within 4 week diagnostic procedure ( eg incision , needle biopsy ) within 1 day study drug administration . k ) Known drug alcohol abuse . l ) Presence underlie medical condition opinion Investigator Sponsor could adversely affect ability subject comply tolerate study procedure and/or study therapy , confound ability interpret tolerability combine administration DS8273A nivolumab treat subject . 3 ) Allergies Adverse Drug Reaction ) History allergy component nivolumab DS8273A , know allergy antibody therapy . 4 ) Sex Reproductive Status 1 . WOCBP unwilling unable use acceptable method minimize risk pregnancy entire study period least 23 week last dose investigational product . 2 . Women pregnant breastfeeding . 3 . Women positive pregnancy test enrollment prior investigational product administration . 4 . Sexually active fertile men use effective birth control partner WOCBP . 5 ) Prohibited Prior Treatments and/or Therapies ) Exposure investigational drug within 4 week study drug administration . b ) Any anticancer therapy ( eg , chemotherapy , biologics , radiotherapy , hormonal treatment ) within 4 week least 5 halflives ( whichever longer ) study drug administration . c ) Prior therapy antiPD1/PDL1 antibody TRAILDR5 antibody ) Concurrent chemotherapy , hormonal therapy , immunotherapy regimen , radiation therapy , standard investigational . 6 ) Other Exclusion Criteria 1 . Prisoners subject involuntarily incarcerate 2 . Subjects compulsorily detain treatment either psychiatric physical ( eg , infectious disease ) illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>TRAIL-DR5</keyword>
	<keyword>DS-8273a</keyword>
	<keyword>Immunoglobulin gamma-1 ( IgG1 )</keyword>
	<keyword>Cell mediate cytotoxicity ( ADCC )</keyword>
	<keyword>Complement dependent cytotoxicity ( CDC )</keyword>
	<keyword>DR5</keyword>
	<keyword>Immunoglobulin G4 ( IgG4 )</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Programmed Cell Death 1 ( PD-1 )</keyword>
</DOC>